#United States #Princeton #Bracco Diagnostics #VUEWAY #MRI Contrast

Bracco Reaches Major Milestone with VUEWAY® Doses

Bracco Diagnostics Inc., the U.S. arm of Bracco Imaging S.p.A., has made a remarkable announcement regarding its MRI contrast agent, VUEWAY® (gadopiclenol). The company has successfully administered over three million doses across 902 customer sites since gaining FDA approval, underscoring both strong market adoption and a growing preference among patients for lower-dose contrast agents.

Importance of VUEWAY® in Medical Imaging

VUEWAY® is a macrocyclic gadolinium-based contrast agent (GBCA) specifically designed to enhance magnetic resonance imaging (MRI) while utilizing half the gadolinium dose compared to other approved agents in the United States. Administering only 0.05 mmol/kg of gadolinium allows for reduced cumulative exposure without compromising the quality of the images produced. This is particularly significant when considering the critical role contrast-enhanced MRI plays in diagnosing and monitoring conditions such as breast cancer and multiple sclerosis.

Noelle Heber, Executive Director of the Radiology Platform at Bracco Diagnostics, remarked, "Innovation should always start with the patient, and the rapid adoption of VUEWAY® injection shows that the industry agrees. This milestone of three million doses highlights the power of combining safety, efficacy, and patient preference in a single solution. We are grateful to the imaging community for their trust."

Patient Preferences Shaping MRI Practices

The announcement follows the results of a nationally representative survey that Bracco commissioned among 300 MRI patients who received treatment with contrast in the past year. Results showed overwhelming support for lower-dose gadolinium agents:

• - 92% expressed interest in using an agent with half the gadolinium dose.
• - 90% were willing to travel a minimum of 25 miles to have access to a lower-dose option.
• - Remarkably, 85% undergoing routine breast cancer screening displayed a strong interest in a half-dose alternative.

Among patients suffering from multiple sclerosis, 78% favored a reduced gadolinium dosage for upcoming scans, indicating an emerging awareness of safety and an active engagement in their healthcare decisions.

Safety and Efficacy Supported by Data

Since its market introduction, VUEWAY® has not only garnered positive feedback from patients but has also demonstrated a strong safety profile backed by extensive real-world data. In the first year of clinical use, a post-marketing safety study evaluated 882,550 administrations of VUEWAY®. The study reported:

• - No serious adverse events.
• - Only 32 patients reported adverse events out of all administrations.

These findings reflect a commitment from Bracco to uphold patient safety while innovating with new solutions in diagnostic imaging. Dr. Todd Mulderink, Chairman of Radiology at Corewell Health Grand Rapids, described the contrast agent as "a game-changer and a win for both patients and radiologists."

Bracco's Commitment to Innovation

With patient safety, efficacy, and a focus on minimizing gadolinium exposure, VUEWAY® is carving out its place as a preferred choice for patients who require multiple MRI exams over time. Moving forward, Bracco will continue to invest heavily in innovation and education to empower patients and clinicians alike, ensuring safe, informed choices in imaging practices.

In addition to VUEWAY®, Bracco is dedicated to delivering a broad portfolio of pharmaceutical products, including contrast agents for computed tomography (CT) and ultrasound, reinforcing their commitment to advancing the field of radiology.

For further information on VUEWAY® and its safe administration, consult the full prescribing information available through Bracco Diagnostics. VUEWAY is a registered trademark of Bracco Imaging S.p.A.